ATLANTA, GA – May 17, 2017 – Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Akari Therapeutics, Plc (“Akari Therapeutics” or the “Company”) (NASDAQ: AKTX) securities between March 30, 2017 and May 11, 2017. The lawsuit alleges that Akari Therapeutics issued certain false and misleading statements that failed to disclose that: (1) Akari Therapeutics’s CEO, and possibly other executives, were involved in publishing false information about Akari Therapeutics, including false information about the Phase 2 PNH trial of Coversin; (2) Akari Therapeutics lacked adequate checks and protections to prevent such behavior; and (3) as a result, defendants’ statements about Akari Therapeutics’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. According to the complaint, Akari Therapeutics’ financial results issued during that time were misleading as a result. If you purchased Akari Therapeutics common stock between March 30, 2017 and May 11, 2017 and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Marshall P. Dees, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832. The deadline to ask the court to be appointed lead plaintiff is July 11, 2017.